Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1634P - Communication specifics with cancer patients during the COVID-19 pandemic in Croatia: Can a virtual visit meet the needs of cancer patients?

Date

16 Sep 2021

Session

ePoster Display

Topics

COVID-19 and Cancer;  Rare Cancers

Tumour Site

Presenters

Renata Kelemenic-Drazin

Citation

Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713

Authors

R. Kelemenic-Drazin1, N. Svilicic2, A. Budisavljevic3, N. Dedic Plavetic4, I. Kardum Fucak5, T. Silovski4, V. Telesmanic Dobric6, M. Nalbani7, Z. Curic7, Z. Boric-Mikez8, T. Ladenhauser9, D. Trivanovic3, Z. Vojnovic1, I. Tomas9, S. Plestina4

Author affiliations

  • 1 Department For Hematology, Oncology And Clinical Immunology, General Hospital Varazdin, 42000 - Varazdin/HR
  • 2 Media And Communication, University North Croatia, 48000 - Koprivnica/HR
  • 3 Department Of Hematology And Oncology, General Hospital Pula, 52100 - Pula/HR
  • 4 Department Of Oncology, University Hospital Centre Zagreb, 10000 - Zagreb/HR
  • 5 Department Of Gastroenterology, Hematology And Oncology, General Hospital Dr Tomislav Bardek Koprivnica, 48000 - Koprivnica/HR
  • 6 Department Of Oncology And Nuclear Medicine, General Hospital Zadar, 23000 - Zadar/HR
  • 7 Department Of Oncology, General Hospital Dubrovnik, 20000 - Dubrovnik/HR
  • 8 Department Of Hematology And Oncology, General Hospital Dr Josip Bencevic Slavonski Brod, 35000 - Slavonski Brod/HR
  • 9 Department Of Oncology, University Hospital Centre Osijek, 31000 - Osijek/HR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1634P

Background

In this study, we focused on communicating with cancer patients on active treatment during the first lockdown due to the COVID-19 pandemic and the patient’s main sources of pandemic information.

Methods

In the first wave of the pandemic, during the first lockdown, we conducted an observational study in 8 of the 13 oncology centers in Croatia. The study is based on an anonymous self-report questionnaire designed for this study. It included 422 oncology patients, older than 18 years, who were in active oncology treatment at the time. To study the correlation between the patient’s perspective on communicating with medical staff during a pandemic, the preferred type of communication, and the main sources of pandemic information relative to clinical and sociodemographic data, we used univariate descriptive and bivariate analyzes.

Results

In the first lockdown, our respondents communicated with the oncologist and oncology nurses mostly in-person (77.7% vs. 81%), and with the general practitioner mostly virtually, most often by phone (70.6%). Regardless of the pandemic, the majority of oncology patients (76.1%) prefer to communicate with an oncologist in-person, and most expressed satisfaction with communicating with medical staff during a pandemic. The choice of information sources and type of communication depends on the age, gender, income, education, and the seat of the disease of patients.

Conclusions

For most of our respondents, in-person visits were the basic way of communicating with oncologists and oncology nurses. On the other hand, a virtual visit was the basic way to communicate with the general practitioner. As patients stated that, regardless of the pandemic, they prefer to communicate with the oncologist in-person, we can conclude that the virtual visit does not meet the needs of cancer patients who are in active oncology treatment. In our study men showed a tendency to communicate in-person, while women, breast cancer patients, younger people, highly educated people, and people of higher income are more prone to virtual visits and are more inclined to use the Internet as a source of information about a pandemic.

Clinical trial identification

Approval number: 02/1-91/97-2020.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.